Alvotech (NASDAQ:ALVO) is one of the best oversold NASDAQ stocks to buy now. On July 9, Alvotech (NASDAQ:ALVO) announced that ...

Alvotech (ALVO) has been on a downward spiral lately with significant selling pressure. After declining 6.6% over the past ...

Alvotech stock has dropped despite strong fundamentals and rapid sales growth. Read about ALVO's projected revenue, debt ...

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for ...

Alvotech acquires Swiss packaging firm Ivers-Lee to boost biosimilar production capacity ahead of three 2025 launches.

Alvotech, a global biotech company specializing in the development and manufacture of biosimilars, has appointed Linda ...

Max Kettner, chief multi-asset strategist at HSBC, appeared on CNBC to talk about the global markets amid trade tensions.

Joel Morales, who has served as CFO of Alvotech since 2020, based in the U.S., has decided to step down. He will continue supporting Alvotech in an advisory capacity to ensure a smooth transition.

Inventiva named Jason Campagna as president of R&D and chief medical officer, and Martine Zimmermann as EVP of regulatory affairs and quality assurance. Evolent named Dr. David Lim as chief clinical ...

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for ...

Alvotech and Advanz Pharma expand their European biosimilar partnership to include AVT10, targeting Cimzia® for rheumatic ...

Alvotech, Kashiv, and Advanz announce successful efficacy study results for AVT23, a proposed biosimilar to Xolair® for CSU treatment.